Business
Presentation of KidneyIntelX Health Economics Data
Presentation of KidneyIntelX Health Economics Data.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n RNS Number : 7987H\n Renalytix AI PLC\n 27 March 2020\n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n (\"RenalytixAI\", the \"Company\")\n \n \n \n \n \n Presentation of KidneyIntelX™ Health Economics Data\n \n \n \n \n \n Renalytix AI plc \n (LSE\n : RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that further to RNS Reach 2937H on 24 March 2020, Boston Healthcare Associates has presented data on KidneyIntelX™, the Company's AI-enabled in vitro diagnostic test for kidney disease, and the clinical and health economic benefit from deploying the test in large health systems in the United States during National Kidney Foundation's Spring Clinical Meeting. \n \n \n \n \n \n A poster summarizing the data presented by Boston Healthcare is now available through the conference website and at \n \n \n https://renalytixai.com/investors/utility-and-impact-of-kidneyintelx\n \n \n \n .\n \n \n \n \n \n \n \n \n It is estimated that there are 12 million individuals with diabetic kidney disease (DKD) in the United States alone. The economic impact model estimates that KidneyIntelX™ testing of 100,000 individuals with DKD, with the assumption of a 20% relative decrease in DKD progression for the 16% of DKD individuals scored as \"high-risk\" by KidneyIntelX™ patients, could deliver cumulative savings of more $1 billion over a five-year period. The presentation was delivered by Thomas Goss, PharmD, Senior Vice President, Boston Healthcare Associates. \n \n \n \n \n \n During the presentation, Dr. Goss described the population health benefits that can be realized with system-wide adoption of KidneyIntelX™. These include delaying progression to more advanced stages of DKD, reducing hospitalizations, and avoiding unplanned emergency room crashes onto dialysis, and delaying or preventing end stage kidney disease, and related dialysis and kidney transplant procedures. These outcomes will not only lead to a significant improvement in quality of life for diabetic kidney disease patients, they also can drive significant cost benefit for health providers and insurers. The model developed by Boston Healthcare demonstrates that a health insurer will realize net savings in less than two yea...